Eikon Therapeutics, Inc. EIKN
Eikon Therapeutics, Inc. (Nasdaq: EIKN) is an oncology drug developer. Its lead program, EIK1001, is in Phase 2 for First-line advanced melanoma (with pembrolizumab); also NSCLC. Its next catalyst on record is EIK1003 Cohort 1B: Initial clinical data at ESMO (October 2026).
Upcoming catalysts
- October 2026EIK1003 Cohort 1B — Initial clinical data at ESMO
We plan to present initial clinical data from Cohort 1B at the ESMO Congress 2026 in October.
- October 2026EIK1004 — First clinical data at ESMO
We plan to present the first clinical data from this trial at the ESMO Congress 2026 in October.
- October 2026EIK1005 — Initial clinical data at ESMO
We plan to present initial clinical data from this trial at the ESMO Congress 2026 in October 2026.
Next further out: EIK1006 — IND submission (2026). 6 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| EIK1001 (TeLuRide-006) | First-line advanced melanoma + pembrolizumab (Phase 2/3 registrational) | small molecule | Phase 2 |
| EIK1001 (TeLuRide-008) | First-line stage 4 NSCLC + pembrolizumab + chemo (Phase 2/3 registrational, first patient dosed July 2026) | small molecule | Phase 2 |
| EIK1001 (TeLuRide-005) | NSCLC + pembrolizumab + chemotherapy (Phase 2, enrollment complete) | small molecule | Phase 2 |
| EIK1003 | Ovarian, breast, prostate, pancreatic cancers (selective PARP1 inhibitor) | small molecule | Phase 2 |
| EIK1004 | Ovarian, breast, prostate, pancreatic cancers incl. brain metastases (brain-penetrant PARP1 inhibitor) | small molecule | Phase 1 |
| EIK1005 | MSI-high solid tumors (WRN helicase inhibitor) | small molecule | Phase 1 |
| EIK1006 | Prostate cancer (next-generation AR antagonist) | small molecule | Pre-clinical |
Recent results and decisions
- Oct 23, 2026positive EIK1003 monotherapy showed 14.3% ORR overall (31.3% in PARP-naïve patients) with generally well-tolerated safety profile in updated Phase 1/2 data.
Updated data from EIK1003-001 demonstrate that highly selective non-brain-penetrant PARP1 inhibitor EIK1003 as monotherapy (Cohort 1A) was generally well-tolerated across multiple dose levels.
Filing - Oct 23, 2026positive EIK1003 combined with abiraterone showed 20.8% ORR and 30.8% PSA response rate with favorable tolerability in metastatic prostate cancer.
In Cohort 1B, EIK1003 in combination with the novel hormonal agent abiraterone is observed to have a favorable tolerability profile with preliminary signs of clinical activity.
Filing - Oct 23, 2026positive EIK1004 monotherapy demonstrated 12.1% ORR with minimal hematologic toxicity and generally well-tolerated safety profile in initial Phase 1/2 data.
EIK1004 was observed to be generally well-tolerated across multiple dose levels with no treatment-emergent dose-limiting toxicities (DLTs) reported, with the majority of TEAEs being low grade.
Filing
4 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 oncology companies
- Tango Therapeutics, Inc. TNGX
- Tyra Biosciences, Inc. TYRA
- Verastem, Inc. VSTM
- Obsidian Therapeutics, Inc. OBX
- Puma Biotechnology, Inc. PBYI
- Fulgent Genetics, Inc. FLGT
- Delcath Systems, Inc. DCTH
- Unknown Unknown
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.